UK MHRA does not favour introducing additional pre-market scrutiny for high-risk devices in EU
This article was originally published in Clinica
Executive Summary
The Medicines and Healthcare products Regulatory Agency has told a UK parliamentary committee that it does not support the concept of introducing pre-market scrutiny for high-risk devices marketed in the EU in addition to that undertaken by notified bodies.
You may also be interested in...
EU Regulators Explain How To Ensure Transitioned Trials Align With CTR
Members of the EU’s Clinical Trials Coordination Group have developed harmonized requirements for updating trials that are transitioned to the Clinical Trials Information System based on a minimum set of documents.
Global Medtech Guidance Tracker: March 2024
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Fifty-nine documents have been posted on the tracker since its last update.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.